These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8562291)

  • 1. Zidovudine therapy in HIV infection: which patients should be treated and when.
    Barry MG; Back DJ; Breckenridge AM
    Br J Clin Pharmacol; 1995 Aug; 40(2):107-10. PubMed ID: 8562291
    [No Abstract]   [Full Text] [Related]  

  • 2. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.
    Bhana N; Ormrod D; Perry CM; Figgitt DP
    Paediatr Drugs; 2002; 4(8):515-53. PubMed ID: 12126455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral drugs: new agents, new combinations line up against HIV.
    Phillips L
    Hosp Technol Ser; 1996 Jan; 15(1):1-3. PubMed ID: 10161344
    [No Abstract]   [Full Text] [Related]  

  • 4. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.
    Suksomboon N; Poolsup N; Ket-Aim S
    J Clin Pharm Ther; 2007 Jun; 32(3):293-311. PubMed ID: 17489882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment during primary HIV infection shows promise.
    Am J Health Syst Pharm; 1995 Nov; 52(21):2383-4. PubMed ID: 8564599
    [No Abstract]   [Full Text] [Related]  

  • 6. Zidovudine (Retrovir).
    Res Initiat Treat Action; 2000 Mar; 6(1):6-7. PubMed ID: 11708188
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nevirapine approved by FDA. Food and Drug Administration.
    Bowersox J
    NIAID AIDS Agenda; 1996 Sep; ():10. PubMed ID: 11363918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors.
    Walker VE; Poirier MC
    Environ Mol Mutagen; 2007; 48(3-4):159-65. PubMed ID: 17358025
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.
    Kleim JP; Winters M; Dunkler A; Suarez JR; Riess G; Winkler I; Balzarini J; Oette D; Merigan TC
    J Infect Dis; 1999 Mar; 179(3):709-13. PubMed ID: 9952383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with saquinavir.
    Vella S
    AIDS; 1995 Dec; 9 Suppl 2():S21-S25. PubMed ID: 8775803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral resistance: a major challenge in managing HIV disease.
    Boucher CA; Reedijk M
    J Biol Regul Homeost Agents; 1995; 9(3):91-4. PubMed ID: 8782014
    [No Abstract]   [Full Text] [Related]  

  • 14. A fossil record of zidovudine resistance in transmitted isolates of HIV-1.
    Kuritzkes DR
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13485-7. PubMed ID: 11717419
    [No Abstract]   [Full Text] [Related]  

  • 15. Two studies suggest nevirapine benefit for children.
    AIDS Patient Care STDS; 1997 Jun; 11(3):195. PubMed ID: 11361798
    [No Abstract]   [Full Text] [Related]  

  • 16. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Aug; (8):CD008651. PubMed ID: 20687097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Basic and clinical aspects of drug resistance in human immunodeficiency virus type 1 infection].
    Salomon HE; Pampuro SE; Gu Z; Montaner JS; Libonatti O; Wainberg MA
    Rev Argent Microbiol; 1995; 27(4):214-29. PubMed ID: 8850135
    [No Abstract]   [Full Text] [Related]  

  • 18. New formulations approved for children.
    AIDS Patient Care STDS; 2008 Jan; 22(1):88. PubMed ID: 18453043
    [No Abstract]   [Full Text] [Related]  

  • 19. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
    Eron JJ; Benoit SL; Jemsek J; MacArthur RD; Santana J; Quinn JB; Kuritzkes DR; Fallon MA; Rubin M
    N Engl J Med; 1995 Dec; 333(25):1662-9. PubMed ID: 7477218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.